NASHVILLE, Tenn. / Feb 13, 2024 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Michael R. McAlevey, senior vice president and chief legal officer, will be promoted to executive vice president – chief legal and administrative officer.
McAlevey joined HCA Healthcare in 2022 from General Electric Company. In his expanded role, McAlevey will oversee a newly consolidated organization to manage enterprise risk and external affairs. In addition to the legal department he currently oversees, he will assume responsibility for marketing and corporate affairs, government relations, development, ethics and compliance and information protection and security.
In addition, HCA Healthcare announced the following reporting changes among its senior leadership team:
“These changes are part of our ongoing endeavor to streamline efforts and align organizationally around key strategic initiatives,” said Hazen. “We will continue to maintain an efficient and transparent organizational process underneath this new structure that allows us to conduct the company’s business consistent with our past practices.”
Unless otherwise noted, these changes will be effective April 1, 2024.
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 186 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its more than 43 million annual patient encounters to advance science, improve patient care and save lives.
All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.
Last Trade: | US$335.55 |
Daily Change: | -5.07 -1.49 |
Daily Volume: | 974,226 |
Market Cap: | US$84.990B |
February 20, 2025 February 18, 2025 October 25, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load